Raymond James Financial Services Advisors, Inc. - IRONWOOD PHARMACEUTICALS INC ownership

IRONWOOD PHARMACEUTICALS INC's ticker is IRWD and the CUSIP is 46333X108. A total of 252 filers reported holding IRONWOOD PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.2%.

Quarter-by-quarter ownership
Raymond James Financial Services Advisors, Inc. ownership history of IRONWOOD PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$133,347
-9.0%
13,847
+0.6%
0.00%
Q2 2023$146,523
+1.5%
13,771
+0.3%
0.00%
Q1 2023$144,387
-15.7%
13,725
-0.7%
0.00%
Q4 2022$171,193
+20.6%
13,817
+0.5%
0.00%
Q3 2022$142,000
-12.3%
13,745
-2.2%
0.00%
Q2 2022$162,000
+6.6%
14,048
+16.6%
0.00%
Q1 2022$152,000
+9.4%
12,048
+0.7%
0.00%
Q4 2021$139,000
-7.9%
11,963
+3.6%
0.00%
Q3 2021$151,000
+1.3%
11,5460.0%0.00%
Q2 2021$149,000
+6.4%
11,546
-8.0%
0.00%
Q1 2021$140,000
+6.1%
12,546
+8.7%
0.00%
Q4 2020$132,000
+26.9%
11,5460.0%0.00%
Q3 2020$104,000
-11.9%
11,546
+1.3%
0.00%
Q2 2020$118,000
+2.6%
11,3960.0%0.00%
-100.0%
Q1 2020$115,000
-24.3%
11,3960.0%0.00%
Q4 2019$152,000
+55.1%
11,3960.0%0.00%
Q3 2019$98,000
-22.8%
11,396
-1.7%
0.00%
Q2 2019$127,000
-28.2%
11,596
+1.0%
0.00%
-100.0%
Q1 2018$177,000
+2.9%
11,4830.0%0.00%0.0%
Q4 2017$172,000
-7.0%
11,483
-2.1%
0.00%0.0%
Q3 2017$185,000
-19.6%
11,733
-3.5%
0.00%
-50.0%
Q2 2017$230,000
+11.1%
12,1610.0%0.00%0.0%
Q1 2017$207,000
+20.3%
12,161
+8.0%
0.00%
+100.0%
Q4 2016$172,00011,2630.00%
Other shareholders
IRONWOOD PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 16,390,000$157,835,70021.26%
AlphaCentric Advisors LLC 292,500$2,816,7751.60%
Quantedge Capital Pte Ltd 179,900$1,732,4370.94%
Intrinsic Value Partners, LLC 50,355$484,9190.62%
Brown Capital Management 3,719,796$35,821,6350.55%
ARMISTICE CAPITAL, LLC 3,456,000$33,281,2800.51%
SummerHaven Investment Management, LLC 67,765$652,5770.48%
BRAIDWELL LP 1,348,099$12,982,1930.41%
AFFINITY INVESTMENT ADVISORS, LLC 50,733$488,5590.32%
EMC Capital Management 43,315$4170.31%
View complete list of IRONWOOD PHARMACEUTICALS INC shareholders